Table 5.
CRP-related markers in previous reports on colorectal cancer.
| Year | Author | Markers | Population | Patient (n) | Cutoff |
|---|---|---|---|---|---|
| 2008 | Koike et al. [87] | CRP | CRC following surgery (all stages) | 300 | 0.5 |
| 2016 | Ishizuka et al. [27] | CAR | CRC following surgery (all stages) | 627 | 0.038 |
| 2017 | Ide et al. [88] | CAR | rectal cancer following CRT and surgery (Stage I–III) | 115 | 0.049 |
| 2018 | Dolan et al. [36] | CAR | CRC following curative resection (Stage I–III) | 801 | 0.22 |
| 2019 | Okugawa et al. [89] | LCR | CRC following surgery (all stages) | 477 | 6000 |
| 2020 | Matsuoka et al. [90] | CAR | CRC following curative resection (Stage III) | 133 | 0.035 |
| 2020 | Suzuki et al. [91] | LCR | CRC following curative resection (Stage II–III) | 1303 | 12980 |
| 2021 | Yasui et al. [52] | CAR | CRC following curative resection (Stage III) | 563 | 0.025 |
| 2021 | Yasui et al. [52] | LCR | CRC following curative resection (Stage III) | 563 | 10424 |
| 2021 | Taniai et al. [92] | CLR | CRLM following liver resection | 197 | 62.8 × 10−6 |
CRP: C-reactive protein, CRC: colorectal cancer, CRLM: colorectal liver metastasis, nCRT: neoadjuvant chemoradiotherapy, CAR: C-reactive protein–albumin ratio, LCR: lymphocyte–C-reactive protein ratio, CLR: C-reactive protein–lymphocyte ratio.